July 07, 2026

Medical Oddities: When a Brush Beats a Scalpel

This research roundup has brain drama, bleeding control, skin science, and tiny brushes.

Conexiant

July 07, 2026

More Physicians Enter Politics

Viewpoint explores how more physician-candidates could reshape both public service and public trust in medicine.

Conexiant

July 02, 2026

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

Conexiant

July 02, 2026

Does Structured Reporting Improve Lung Cancer Reports?

A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.

Conexiant

July 02, 2026

Immediate Repair Successful After Urethral Injury

Case report described successful immediate reconstruction of a membranous urethral injury recognized during rectal cancer surgery.

Conexiant

July 01, 2026

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Conexiant

June 30, 2026

FDA Names PreCheck Participants

Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.

Conexiant

June 30, 2026

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

Conexiant

June 29, 2026

GCS May Expand CTRCD Assessment

Award-winning ASE abstract highlights GCS when GLS assessment is limited by suboptimal apical windows.

Conexiant

June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Conexiant